Skip to main content

Advertisement

Table 3 Association between mutated single markers in pfcrt, pfmdr1, pfdhfr and pfdhps and treatment failure with amodiaquine plus sulphadoxine-pyrimethamine

From: The usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New Guinea

Gene Polymorphism OR 95% Confidence Interval p(LRT)
pfcrt K76T 2.09 0.45–9.70 0.31
pfcrt I326L 2.64 0.58–12.03 0.16
pfcrt N356D 2.64 0.58–12.03 0.16
pfcr A220S 1.23 0.55–2.75 0.62
pfmdr1 N86Y 7.87 1.03–60.36 <0.01
pfmdr1 Y184F §   
pfmdr1 N1042D §   
pfdhfr S108N 0.74 0.22–2.51 0.64
pfdhfr C59R 2.34 0.77–7.14 0.11
pfdhps A437G 3.44 1.40–8.47 <0.01
pfdhps K540E §   
  1. OR, odds ratio; LRT, likelihood ratio test; pfcrt, Plasmodium falciparum chloroquine resistance transporter; pfmdr1, Plasmodium falciparum multidrug resistance gene 1; pfdhfr, Plasmodium falciparum dihydrofolate reductase; pfdhps, Plasmodium falciparum dihydropteroate synthase; § mutated alleles were not detected in samples from treatment failure cases